in this issue
Regions :: North America
Sun Pharma and Intrexon form new therapeutics joint venture
8:01 AM MDT | October 6, 2013 | Natasha Alperowicz
Sun Pharma (Mumbai) and Intrexon Corp. (Germantown, MD), a leader in synthetic biology, have announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness. Initial targets are dry age-related macular degeneration (AMD), glaucoma and retinitis pigmentosa. The joint venture will leverage Sun Pharma’s global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee